Skip to main content

Advertisement

Table 5 Hematologic and nonhematologic adverse events which ever occurred in 39 patients treated with FOLFIRINOX as a second-line treatment

From: Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

Adverse event Any grade Grade 3 or more
Number of patients % Number of patients %
Hematologic
 Neutropenia 18 46.2 16 41.0
 Thrombocytopenia 7 17.9 1 2.6
 Anemia 23 59.0 3 7.7
Nonhematologic
 Nausea 23 59.0 4 10.3
 Vomiting 3 7.7 1 2.6
 Diarrhea 11 28.2 1 2.6
 Fatigue 9 23.1 2 5.1
 Anorexia 21 53.8 4 10.3
 Constipation 6 15.4   
 Mucositis 12 30.8 3 7.7
 Neuropathy 5 12.8 1 2.6
 Septic shock    1a 2.6
 Pneumonia/pleural effusion    2 5.1
 Abdominal distension    1 2.6
 Alkaline phosphatase increased    1 2.6
 Hypokalemia    1 2.6
 Glossopharyngeal neuralgia    1 2.6
  1. aGrade 5 (death)